AbbVie signs heavily backloaded $2.1B Xilio biobucks pact in Big Pharma's latest T-cell engager deal
Having kicked off the year with a T-cell engager deal, AbbVie has returned to the modality. | Having kicked off the year with ...
Sanofi-backed Abcuro has secured $200 million in series C funds to power its anti-KLRG1 antibody through a phase 2/3 muscle ...
More than 13 years after its initial FDA approval, Pfizer’s blood cancer drug Adcetris has nabbed another regulatory green ...
Also entered into collaboration and option agreement with AbbVie to develop novel tumor-activated immunotherapies, including masked T cell ...
GlobalData on MSN13d
Leveragen and Moonlight Bio unite for T-cell therapy developmentLeveragen has announced a strategic partnership with Moonlight Bio, targeting the development of T-cell therapies for ...
Korean researchers develop Trojan horse method to produce antibodies in tumors Innovative nanoparticle platform creates tumor ...
News Medical on MSN9h
Dual-target drug may lead to new treatment approach for breast cancer patientsResearchers, led by the University of Melbourne's Professor Laura Mackay, a Laboratory Head and Immunology Theme Leader at ...
Collaboration will combine AbbVie's oncology expertise and Xilio's proprietary tumor-activation technology to develop novel immunotherapies, including masked T-cell engagersXilio to host investor ...
The Boston-area company’s previous raises were also aimed at getting its investigational antibody treatment for inclusion ...
AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, published an announcement on February 11, 2025, announced that its independently developed mRNA shingles vaccine has been submitted for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback